NAD Augmentation in Diabetes Kidney Disease (NCT05759468)
NAD Augmentation to Treat Diabetes Kidney Disease: A Randomized Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (12 items) and avoid the listed exclusions (14 items).
Location: Brigham and Women's Hospital — Boston, Massachusetts
Age range: 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion criteria:
- Fasting morning UACR \> 5,000 mg/ g creatinine
- Other laboratory abnormalities:
- Has AST or ALT \> 3 times the upper limit of normal
- eGFR \< 25 mL/ min / 1.73 m2
- Hematocrit \< 0.34 or \> 0.50 L/L
- A major adverse cardiovascular event in preceding 3 months
- Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
- Current alcohol or substance use disorder or dependence (DSM 5 criteria).
- Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures.
- An acute illness, including COVID-19, requiring hospitalization within the past 3 months or any acute illness, including COVID-19, within the past month.
- Has a history of anaphylaxis from vitamin B3 derivatives
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Brigham and Women's Hospital — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 525-9150
Email: sbhasin@bwh.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type2diabetes
- The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction — Rochester, Minnesota
- Non-weight Bearing Exercise for Accelerated Healing of Diabetic Foot Ulcers — Ann Arbor, Michigan
- Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment — Galveston, Texas
- The CARING Study: Creating and Restoring Health Through Nutrition Guidance — Washington D.C., District of Columbia
- Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure — Baltimore, Maryland
Explore by condition: All Type2diabetes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.